Dow Inc. (DOW)

FairStock Score: 45/100 — MIXED

Key Financials

Strengths

• Low beta of 0.71 provides relative stability vs. market volatility
• Diversified geographic footprint across multiple regions reduces concentration risk
• Market-leading position in basic chemical intermediates with 34,600 employees indicating established operations
• Current price near lower end of 52-week range ($20.40-$38.36) offers some valuation cushion

Concerns

• Negative free cash flow of $784.8M annually with no clear turnaround timeline
• Latest quarter loss of $1.5B on $9.5B revenue indicates severe profitability crisis, not normal cyclicality
• ROE of -13.82% and ROCE of -0.07% show capital destruction rather than value creation
• Altman Z-Score of 1.10 places company in financial distress zone with elevated bankruptcy risk

AI Analysis

I'm examining Dow Inc. with considerable skepticism. This is a capital-intensive chemical manufacturer trading at 1.64x book value, which might seem reasonable until we examine the fundamentals. The latest quarter reveals a $1.5B loss on $9.5B in revenue—a catastrophic -16.31% margin that suggests either temporary cyclical distress or structural deterioration. Most concerning: negative free cash flow of $784.8M annually and a Piotroski F-Score of just 3/9 indicates deteriorating business quality. The company's ROE of -13.82% and ROCE of -0.07% tell me capital is being destroyed, not created. With debt-to-equity at 1.12, they're leveraged into a difficult cycle. The Altman Z-Score of 1.10 places them in distress territory—between 1.0 and 1.8 is the gray zone where bankruptcy risk becomes material. While the 0.71 beta suggests lower volatility, that's cold comfort when the business itself is unprofitable. Chemicals are cyclical, yes, but this doesn't appear to be normal cyclicality—it's a business generating negative returns on capital. The dividend yield shows as N/A, likely suspended, confirming financial stress. I need to see sustained positive cash flow, margin recovery, and debt reduction before considering this an investment. At $34.31, we're not compensated adequately for the risk. Without a clear path to profitability and positive ROCE, I'll pass.

Bull Case

If commodity chemical prices stabilize and demand recovers, Dow's scale and established market position could generate rapid margin expansion, potentially returning to mid-single-digit ROE within 12-18 months. Management could aggressively reduce debt using operating cash flow recovery, significantly de-risking the balance sheet and unlocking shareholder value.

Bear Case

Structural oversupply in chemicals combined with weak demand could persist, keeping margins compressed and cash flow negative for multiple years. If leverage ratios worsen or refinancing becomes difficult, the company may face equity dilution or covenant violations, destroying remaining shareholder value.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer